We are international
• treatment options TEXT SIZE   
imf research grant awards    back

Rationally Designed Pralatrexate Combination Therapies for MM
Hearn Jay Cho, MD
New York University Medical Center
New York,New York, USA

Pralatrexate is a new drug that is FDA-approved for lymphoma. The effectiveness of this drug is due in part to the presence of a molecule called RFC-1 on tumor cells, and RFC-1 levels in cancer cells can be increased by treatment wit certain drugs that affect gene expression.

Preliminary data indicate that pralatrexate can also kill myeloma cells that express RFC-1. We will determine if pralatrexate can be combined with drugs that increase RFC-1 to efficiently kill myeloma cells. Proof of this concept in laboratory studies may lead to clinical trials of these combinations in myeloma.

 related articles